SATKARTAR

Sat Kartar Life Limited

Listed company · ISIN INE0NB801022 · NSE SM · FV ₹10
Last price
₹132
+4.47%today
What this company does

Sat Kartar Life Limited is a listed company. It booked ₹114 cr of revenue in its latest half year (H1 FY27) and kept 8.1% of sales as profit.

71out of 100
Equitytale Health Score
Solid

Healthier than 71% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,387–2,932 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
40

At close. Not part of the score.

Profitability & returns80

How much profit it earns on the money it employs

Balance sheet86

How much it owes, and whether earnings cover the interest

Cash quality29

Whether reported profit actually arrives as cash

Valuation58

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Looks broadly healthy
Strengths
✓ Makes a profit
✓ Sales up 26% vs last year
✓ Profit up 27% vs last year
✓ Promoters hold 63%
✓ No promoter shares pledged
✓ Strong 31% return on equity
✓ Virtually debt-free
Watch-outs
None flagged from our data

What if I invest in SATKARTAR?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest half year + price
₹132▲ +4.47%
latest close · 2026-11-04
52-wk low ₹11074 sessions so far52-wk high ₹210
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio11.2Low
LowAverageHigh
P/B ratio3.48High
Below bookModerateHigh
EV / EBITDA8.3Average
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity31.0%Strong
WeakFairStrong ▸15%
Return on capital28.5%Strong
WeakFairStrong
Net margin8.1%Decent
ThinDecentStrong
EBITDA margin11.0%Decent
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.04Comfortable
LowModerateHigh ▸1
Interest cover54.3×Strong
RiskyOkayStrong ▸5×
Current ratio5.72Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹208 cr
Book value
₹38
EPS
₹5.88
latest half year
Net debt
₹2 cr
owes more than its cash
Enterprise value
₹210 cr
EBITDA
₹25 cr
annualised
EBIT
₹25 cr
annualised
Operating margin
11.0%
Return on assets
17.9%
Earnings yield
8.90%
P/S
0.91
Sales / share
₹144.8
Tax rate
25.0%
Face value
₹10
Shares
1.6 cr
Working capital
₹71 cr
Current assets
₹86 cr
Current liabilities
₹15 cr
Delivery %
71.1%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest half year; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
Too few reliable models — the filings don't support two independent estimates of value.
Models span ₹110–₹110, midpoint ₹110

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · H1 FY27 (consolidated)
Revenue from Operations₹114 cr
Other Income₹43.1 L
Total Income₹114 cr
Cost of Materials₹0 cr
Purchases of Stock-in-Trade₹9 cr
Inventory Change (±)₹-59.4 L
Employee Benefit Expense₹11 cr
Finance Costs₹23.2 L
Other Expenses₹79 cr
Total Expenses₹102 cr
Profit before Tax₹12 cr
Tax Expense₹3 cr
Net Profit₹9 cr
Net margin on total income8.1%
Where the money goes · H1 FY27
% of total income
Materials + stock-in-trade₹9 cr7.7%
Employee benefit expense₹11 cr9.8%
Finance costs₹23.2 L0.2%
Other expenses₹82 cr71.5%
Tax expense₹3 cr2.7%
Profit for the period₹9 cr8.1%
Total income ₹114 cradds up to ₹100 ✓
Half-yearly results · consolidated (₹ cr)
MetricH1 FY26H2 FY26H1 FY27
Revenue90 cr111 cr114 cr
Total income92 cr111 cr114 cr
Expenses82 cr98 cr102 cr
Profit before tax10 cr13 cr12 cr
Tax3 cr3 cr3 cr
Net profit (owners' share)7 cr10 cr9 cr
Net margin (owners' share, on revenue)8.1%8.9%8.1%
EPS (₹)4.646.225.88
YoY (latest quarter): total income +24.3% · net profit +26.7%
Balance sheet & cash flow · as of Sep 2026
Debt-free
Total assets
₹103 cr
Shareholder equity
₹60 cr
parent shareholders
Total debt
₹2 cr
Cash
₹38 L
Corporate actions
Dividend yield
0.53%
trailing 12 months
Dividend / share (TTM)
₹0.7
Last dividend
₹0.7
ex 21 Aug 2026
ActionDetailEx-date
Dividend₹0.7 / share21 Aug 2026
Who owns it · 2026-09-30
No pledge
Promoter
63.5%
FII / Foreign
0.8%
DII / Domestic
1.9%
Retail / others
33.4%
Promoter stake up 0.2% over the last 5 quarters.
Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 38 named members
owning 63.5% between them · as of 2026-09-30
AJOONI WELLNESS PRIVATE LIMITED36.16%
MANPRIT SINGH CHADHA23.65%
ARCHANA CHADHA1.80%
ARYAMAN SINGH CHADHA0.54%
PRANAV SINGH CHADHA0.54%
AMARJIT CHADHA0.23%
PARAMJIT SINGH CHADHA0.22%
GURMEET SINGH0.15%

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹47 cr raised in May 2026 by selling shares to selected investors

As of Sep 2026, the company says it has spent 9% of what it set aside, leaving ₹43 cr still to be spent.

Healthcare Establishment and Expansion
3%
₹90 L of ₹29 cr
Strategic Acquisitions and Global Expansion
0%
₹0 cr of ₹6 cr
Technology, Branding, and Market Expansion
34%
₹3 cr of ₹9 cr
General Corporate Purpose
10%
₹30 L of ₹3 cr
₹34 cr raised in Jan 2025 by selling shares to the public

As of Sep 2026, the company says it has spent 62% of what it set aside, leaving ₹16 cr still to be spent. Care Rating Limited watches the spending on the exchange’s behalf.

Marketing and Advertisement
originally ₹11 cr
budget changed
96%
₹16 cr of ₹17 cr
Investnment in Technology
originally ₹5 cr
budget changed
43%
₹1 cr of ₹3 cr
Unidentified acquisition
originally ₹5 cr
budget changed
59%
₹2 cr of ₹3 cr
General Corporate Purpose
96%
₹1 cr of ₹1 cr
Capital Expenditure (for purchase of building)
0%
₹0 cr of ₹8 cr
-
now filed as: Capital Expenditure for Ayurveda Hospital
originally ₹0 cr
budget changed
28%
₹2 cr of ₹6 cr

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.